Na Yun Suk, Kim Sang Gyun, Cho Soo-Jeong
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, 03080, Seoul, Republic of Korea.
Gastric Cancer. 2023 Mar;26(2):298-306. doi: 10.1007/s10120-022-01361-2. Epub 2023 Jan 6.
Metachronous gastric cancer (MGC) may develop in patients undergoing curative endoscopic submucosal dissection for early gastric cancer. As gastritis and intestinal metaplasia are notable precursors to gastric cancer, we assessed MGC risk using the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM) systems.
This retrospective cohort study classified the OLGA and OLGIM stages for 916 patients who had undergone endoscopic submucosal dissection for early gastric cancer between 2005 and 2015. MGC development was followed up until 2020 and risk factors were evaluated using the Cox proportional hazards regression analysis.
During a median follow-up of 94 months, MGC developed in 120 subjects. OLGA stages II ~ IV were significantly associated with increased MGC risk (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.05-3.19; HR 2.31, 95% CI 1.22-4.38; HR 2.36, 95% CI 1.16-4.78) in multivariable analysis, even after adjusting for the well-known positive predictor of Helicobacter pylori eradication. OLGIM stages II ~ IV also showed significant association (HR 2.86, 95% CI 1.29-6.54; HR 2.94, 95% CI 1.34-6.95; HR 3.64, 95% CI 1.60-8.29). 5-year cumulative incidence increased with each stage. Helicobacter pylori-eradicated patients with OLGIM stages 0 ~ II had significantly less MGC than non-eradicated patients (4.5% vs 11.8%, p = 0.022), which was not observed with OLGIM stages III ~ IV.
High OLGA and OLGIM stages are independent risk factors for metachronous gastric cancer, with the OLGIM staging system being a better predictor. Patients with OLGIM stages 0 ~ II are a subgroup that may benefit more from Helicobacter pylori eradication.
异时性胃癌(MGC)可能发生在接受早期胃癌根治性内镜黏膜下剥离术的患者中。由于胃炎和肠化生是胃癌的显著前驱病变,我们使用胃炎评估手术关联(OLGA)和胃肠化生评估手术关联(OLGIM)系统评估了MGC风险。
这项回顾性队列研究对2005年至2015年间接受早期胃癌内镜黏膜下剥离术的916例患者的OLGA和OLGIM分期进行了分类。对MGC的发生情况进行随访至2020年,并使用Cox比例风险回归分析评估危险因素。
在中位随访94个月期间,120例患者发生了MGC。在多变量分析中,即使在调整了众所周知的幽门螺杆菌根除阳性预测因素后,OLGA IIIV期与MGC风险增加显著相关(风险比[HR] 1.83,95%置信区间[CI] 1.05 - 3.19;HR 2.31,95% CI 1.22 - 4.38;HR 2.36,95% CI 1.16 - 4.78)。OLGIM IIIV期也显示出显著相关性(HR 2.86,95% CI 1.29 - 6.54;HR 2.94,95% CI 1.34 - 6.95;HR 3.64,95% CI 1.60 - 8.29)。随着分期增加,5年累积发病率升高。OLGIM 0II期的幽门螺杆菌根除患者的MGC显著少于未根除患者(4.5%对11.8%,p = 0.022),而OLGIM IIIIV期未观察到这种情况。
高OLGA和OLGIM分期是异时性胃癌的独立危险因素,其中OLGIM分期系统是更好的预测指标。OLGIM 0~II期患者是可能从幽门螺杆菌根除中获益更多的亚组。